Анализ рисков и финансовых показателей биотех-компаний Coya Therapeutics и Absci

Coya Therapeutics ( NASDAQ:COYA – Get Free Report ) and Absci ( NASDAQ:ABSI – Get Free Report ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends. Risk and Volatility Coya Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Institutional and Insider Ownership 39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Earnings and Valuation This table compares Coya Therapeutics and Absci”s top-line revenue, earnings per share (EPS) and valuation. | Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio Coya Therapeutics | $7.95 million | 14.05 | -$21.23 million | ($1.07) | -4.45 Absci | $2.80 million | 540.57 | -$115.18 million | ($0.80) | -11.03 Coya Therapeutics has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks. Analyst Recommendations This is a summary of recent recommendations and price targets for Coya Therapeutics and Absci, as reported by MarketBeat. | Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score Coya Therapeutics | 1 | 0 | 6 | 0 | 2.71 Absci | 1 | 0 | 8 | 0 | 2.78 Coya Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 222.13%. Absci has a consensus price target of $13.43, indicating a potential upside of 52.25%. Given Coya Therapeutics’ higher possible upside, research analysts clearly believe Coya Therapeutics is more favorable than Absci. Profitability This table compares Coya Therapeutics and Absci’s net margins, return on equity and return on assets. | Net Margins | Return on Equity | Return on Assets Coya Therapeutics | -270.22% | -52.05% | -46.34% Absci | -7,756.38% | -61.71% | -54.52% About Coya Therapeutics ( Get Free Report ) Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. About Absci ( Get Free Report ) Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington. Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.